Anti-Diabetic Drugs Market: By Drug Class, By Diabetes Type, By Route of Administration, By Distribution Channel and Geography Forecast to 2030
Anti-Diabetic Drugs Market was valued at US$ 76 billion in 2023 and is poised to grow at a CAGR of 7.6% from 2024-2030. Diabetes is a long-term medical illness characterized by improper food processing for energy production in the body. It happens when there is an excess of glucose, or sugar, in the blood due to problems with the hormone insulin, which aids in controlling blood sugar levels. Anti-diabetic drugs are medications used to manage diabetes by regulating blood sugar levels. They work in various ways, including increasing insulin production, improving insulin sensitivity, or reducing glucose production by the liver. Soaring the prevalence of diabetes due to lifestyle changes, aging populations, and rising obesity rates is expected to drive the anti-diabetic drugs market growth.
Moreover, the company's growing market position in the diabetes industry is facilitated by a rise in the anti-diabetic drugs market research and development efforts aimed at creating innovative diabetic therapies and gaining product approvals. For instance, the FDA approved Semglee (insulin glargine-fun), a biosimilar of the long-acting insulin analog reference medicine Lantus (insulin glargine) in 2021.
Additionally, the growing approval for antidiabetic drugs and a strong pipeline for antidiabetics are expected to offer significant opportunities for market expansion. However, the expensive nature of new and advanced antidiabetic medications can limit accessibility for some patients. Also, potential side effects of medications that may deter patients and healthcare providers from using certain drugs.
Study Period
2024-2030Base Year
2023CAGR
7.6%Largest Market
Asia-PacificFastest Growing Market
Asia-Pacific
A primary driving factor is the increasing incidence of diabetes worldwide. More people are getting diabetes as a result of rising obesity and sedentary lifestyle rates, which is driving up demand for efficient anti-diabetic drugs. According to the World Health Organization (WHO), as of 2021, approximately 422 million people worldwide have diabetes and diabetes is a leading cause of death and significantly impacts quality of life. Moreover, as the number of people diagnosed with diabetes rises, the demand for effective antidiabetic medications naturally increases. This higher demand drives pharmaceutical companies to invest in the development and marketing of new and innovative treatments.
North America is currently the leading region in the anti-diabetic drug market, driven by high diabetes prevalence, robust healthcare infrastructure, and significant investments in research and development. North America has a significant prevalence of diabetes, particularly in the United States, due to high rates of obesity, sedentary lifestyle, and an aging population. For instance, in the United States, approximately 37.3 million people are estimated to have diabetes, representing about 11.3% of the population as per the Centers for Disease Control and Prevention (CDC) record. Also, North America, especially the United States, is a hub for pharmaceutical innovation and clinical trials, leading to frequent introduction of new treatments. The approval of drugs like Mounjaro (tirzepatide) and Ozempic (semaglutide) in the U.S. highlights the region’s role in advancing diabetes treatment options. Whereas, Europe and Asia Pacific is also rapidly growing market due to increasing diabetes rates, expanding healthcare access, and economic growth.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 76 billion |
|
Market CAGR |
7.6% |
|
By Drug Class |
|
|
By Diabetes Type |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
Download Free Sample Report
The global anti-diabetic drugs market size was valued at US$ 76 billion in 2023 and is projected to grow at a CAGR of 7.6% from 2024-2030.
North America is leading the antidiabetic drug market due to high diabetes prevalence, advanced healthcare systems, and strong research and development.
Key drivers include the rising prevalence of diabetes, advancements in drug development, growing awareness and diagnosis, and government support for diabetes research and care.
Major restraints include high costs of new drugs, potential side effects, regulatory hurdles, and market saturation.
Opportunities include growth in emerging markets, innovative drug delivery systems, combination therapies, and advancements in personalized medicine.
Threats include generic competition, market volatility, patient non-compliance, and evolving disease management guidelines.
In the United States, about 37.3 million people have diabetes, which is approximately 11.3% of the population.
North America leads due to high diabetes prevalence, advanced healthcare infrastructure, significant R&D investments, and high market demand for diabetes treatments.
| 1.Executive Summary |
| 2.Global Anti-Diabetic Drugs Market Introduction |
| 2.1.Global Anti-Diabetic Drugs Market - Taxonomy |
| 2.2.Global Anti-Diabetic Drugs Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Diabetes Type |
| 2.2.3.Route of Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Anti-Diabetic Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Anti-Diabetic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Anti-Diabetic Drugs Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Insulin |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. GLP-1 Receptor Agonists |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. DPP-4 Inhibitors |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. SGLT2 Inhibitors |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Anti-Diabetic Drugs Market By Diabetes Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Type 1 |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Type 2 |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Anti-Diabetic Drugs Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Subcutaneous |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Intravenous |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Anti-Diabetic Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Online pharmacies |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospital Pharmacies |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Retail Pharmacies |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Anti-Diabetic Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Anti-Diabetic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Insulin |
| 10.1.2.GLP-1 Receptor Agonists |
| 10.1.3.DPP-4 Inhibitors |
| 10.1.4.SGLT2 Inhibitors |
| 10.1.5.Others |
| 10.2. Diabetes Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Type 1 |
| 10.2.2.Type 2 |
| 10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Subcutaneous |
| 10.3.3.Intravenous |
| 10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Online pharmacies |
| 10.4.2.Hospital Pharmacies |
| 10.4.3.Retail Pharmacies |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Anti-Diabetic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Insulin |
| 11.1.2.GLP-1 Receptor Agonists |
| 11.1.3.DPP-4 Inhibitors |
| 11.1.4.SGLT2 Inhibitors |
| 11.1.5.Others |
| 11.2. Diabetes Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Type 1 |
| 11.2.2.Type 2 |
| 11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Subcutaneous |
| 11.3.3.Intravenous |
| 11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Online pharmacies |
| 11.4.2.Hospital Pharmacies |
| 11.4.3.Retail Pharmacies |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Anti-Diabetic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Insulin |
| 12.1.2.GLP-1 Receptor Agonists |
| 12.1.3.DPP-4 Inhibitors |
| 12.1.4.SGLT2 Inhibitors |
| 12.1.5.Others |
| 12.2. Diabetes Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Type 1 |
| 12.2.2.Type 2 |
| 12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Subcutaneous |
| 12.3.3.Intravenous |
| 12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Online pharmacies |
| 12.4.2.Hospital Pharmacies |
| 12.4.3.Retail Pharmacies |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Anti-Diabetic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Insulin |
| 13.1.2.GLP-1 Receptor Agonists |
| 13.1.3.DPP-4 Inhibitors |
| 13.1.4.SGLT2 Inhibitors |
| 13.1.5.Others |
| 13.2. Diabetes Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Type 1 |
| 13.2.2.Type 2 |
| 13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Subcutaneous |
| 13.3.3.Intravenous |
| 13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Online pharmacies |
| 13.4.2.Hospital Pharmacies |
| 13.4.3.Retail Pharmacies |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Anti-Diabetic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Insulin |
| 14.1.2.GLP-1 Receptor Agonists |
| 14.1.3.DPP-4 Inhibitors |
| 14.1.4.SGLT2 Inhibitors |
| 14.1.5.Others |
| 14.2. Diabetes Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Type 1 |
| 14.2.2.Type 2 |
| 14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Subcutaneous |
| 14.3.3.Intravenous |
| 14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Online pharmacies |
| 14.4.2.Hospital Pharmacies |
| 14.4.3.Retail Pharmacies |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Novo Nordisk A/s |
| 15.2.2.Sanofi |
| 15.2.3.Merck & Co, Inc. |
| 15.2.4.Eli Lilly and Company |
| 15.2.5.AstraZeneca |
| 15.2.6.Takeda Pharmaceuticals Company Limited |
| 15.2.7.Boehringer Ingelheim International GmbH |
| 15.2.8.Novartis AG |
| 15.2.9.Johnson & Johnson Services, Inc. |
| 15.2.10.Bayer AG |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
